Gary Jacobson, President and CFO of Sinclair ResearchCOLUMBIA, Mo.–(BUSINESS WIRE)–Sinclair Research, one of the leading providers of nonclinical research services, has named Gary Jacobson as President and Chief Financial Officer. In addition to his financial responsibilities, Gary will oversee Sinclair’s commercial, legal, human resources and IT functions.

“I’m delighted to welcome Gary to Sinclair,” said Sinclair Research’s CEO Dr. Guy Bouchard, DVM. “Gary’s leadership experience in the CRO industry will help drive scalable and sustainable growth.”

“With the consolidation of the preclinical CRO industry, Sinclair is in a unique position to grow,” Jacobson said. “Sinclair has a scalable model and significant land to accommodate expansion. I’m impressed with Dr. Bouchard’s achievement here as well as the team of experienced scientific and business leaders he’s assembled, bringing backgrounds and perspective from large multi-national nonclinical CROs. My key focus will be to drive capital investment to support the expansion of our nonclinical services and capacity so we can grow our offering as a single site.”

Prior to Sinclair, Gary was President, Chief Executive Officer and Chief Financial Officer of SNBL USA, Ltd. where he led the effort to turnaround that North American preclinical CRO. He was principal and director of General Biotechnology, LLC, and previously served as Executive Vice President and Chief Financial Officer at Ricerca Biosciences, Executive Vice President and Chief Financial Officer of Harlan Sprague Dawley, Inc. and Chief Operating Officer of Harlan Europe. Gary began his career in the banking industry serving as Senior Vice President and Division Manager of LaSalle National Bank and Senior Vice President of American National Bank.

About Sinclair Research

Sinclair Research Center, a nonclinical contract research organization (CRO), offers animal efficacy models, pharmacokinetics/pharmacodynamics evaluation, IND-enabling program support and specialty toxicology research capabilities to support biopharmaceutical, animal health and medical device development programs. Sinclair is experienced in all research models and the undisputed experts in miniature swine. With more than 50 years’ experience, Sinclair has emerged as a leader in diabetes, dermal, otic and animal health research services with streamlined quality systems supporting both VICH and GLP compliant studies and SEND reporting with no backlog.